The Bitterman Lab is grateful to have been awarded funding from the National Cancer Institute to develop novel AI approaches to understand and monitor side effects of immune checkpoint inhibitors. Immune checkpoint inhibitors dramatically improve prognosis for many cancer patients but come at the cost of a new class of immune-related adverse events that reduce overall quality-of-life and the net benefit of treatment. This proposal seeks to automatically detect immune-related adverse event phenotypes from the electronic health record to support timely, data-driven cancer care that enhances survivorship. To achieve this goal, we will develop and clinically validate advanced informatics and artificial intelligence technologies, such as deep learning language models, to automate immune-related adverse event monitoring and data collection.

This project is a multi-institional collaboration with Rhode Island Hospital/Brown University, Boston Children's Hospital, and Dana-Farber Cancer Institute.

You can learn more about our new grant here.